Ovarian cancer: maintenance niraparib benefits partial chemotherapy responders

  • Del Campo JM & al.
  • J Clin Oncol
  • 7 Jun 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • PFS benefit of maintenance niraparib extends to patients with platinum-sensitive, recurrent ovarian cancer who had a partial response to their last platinum-based chemotherapy, regardless of BRCA status.

Why this matters

  • Findings support niraparib maintenance therapy regardless of response to the last platinum-based therapy.

Study design

  • Data from a multicenter, double-blind, phase 3 ENGOT-OV16/NOVA trial of 553 patients with recurrent ovarian cancer who responded to last platinum therapy.
  • Patients were randomly assigned 2:1 to receive maintenance niraparib or placebo.
  • Funding: TESARO (a GSK company).

Key results

  • 203 had germline BRCA mutation.
  • 49% of patients had a partial response to the last platinum therapy.
  • Patients who received niraparib had significantly prolonged PFS vs placebo, regardless of the best response to the last platinum-based therapy.
    • gBRCA-mutated patients with partial response (HR, 0.24; P=.0001) and with complete response (HR, 0.30; P<.0001>
    • non-gBRCA-mutated patients with partial response (HR, 0.35; P<.0001 and with complete response p=".0082).</li">
  • The most common grade ≥3 AEs with niraparib in patients with partial vs complete responses were thrombocytopenia (25.6% vs 31.0%), anemia (26.1% vs 23.5%), and neutropenia (10.0% vs 12.3%).
  • Patient-reported outcomes were not significantly different between groups.

Limitations

  • Post hoc analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit